Pfizer: 2025 targets unveiled, 2024 forecasts confirmed
(CercleFinance.com) - Pfizer shares are expected to rise on Tuesday on Wall Street after unveiling 2025 targets broadly in line with market forecasts.
The US pharmaceuticals group this morning said that it expected adjusted EPS of $2.80 to $3 for the coming year, with a mid-point of $2.90, compared with the current consensus of $2.88. The New York-based company also expects sales of between $61bn and $64bn, compared with the current consensus of $2.88.
The New York-based company also expects sales of $61bn and $64bn, compared with an analyst consensus of $63.3bn.
Pfizer took the opportunity to confirm its FY 2024 targets, i.e. sales of $61bn to $64bn and adjusted EPS of between $2.75 and $2.95.
CEO Albert Bourla said the company was on track to achieve $4bn in operating cost savings, with a further $500m in cost reductions expected by 2025.
Following these announcements, Pfizer shares were up almost 3% in PMT on Tuesday morning.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The US pharmaceuticals group this morning said that it expected adjusted EPS of $2.80 to $3 for the coming year, with a mid-point of $2.90, compared with the current consensus of $2.88. The New York-based company also expects sales of between $61bn and $64bn, compared with the current consensus of $2.88.
The New York-based company also expects sales of $61bn and $64bn, compared with an analyst consensus of $63.3bn.
Pfizer took the opportunity to confirm its FY 2024 targets, i.e. sales of $61bn to $64bn and adjusted EPS of between $2.75 and $2.95.
CEO Albert Bourla said the company was on track to achieve $4bn in operating cost savings, with a further $500m in cost reductions expected by 2025.
Following these announcements, Pfizer shares were up almost 3% in PMT on Tuesday morning.
Copyright (c) 2024 CercleFinance.com. All rights reserved.